ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (Nasdaq: AMRI) and Proteros Biostructures GmbH (Proteros) announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.